生物制药公司Kupando宣布已获得额外1000万欧元A轮融资-动脉网

Biotech start-up secures €23 million total for cancer and infectious disease platform

D-Pharm 等信源发布 2026-03-20 13:08



可切换为仅中文







Kupando, a pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate

Kupando，一家开发生物制药的先锋公司，正在开发一种刺激先天免疫的TLR 4/7激动剂

immunity

免疫力

and induces trained immunity for use in

并诱导训练免疫以用于

oncology

肿瘤学

and

和

infectious diseases

传染病

, announced that it has secured an additional €10 million in

，宣布已获得额外的1000万欧元

Series A financing

A轮融资

. This latest investment brings Kupando’s total Series A funding to €23 million.

这家最新的投资使 Kupando 的 A 轮融资总额达到 2300 万欧元。

The investment was again led by Remiges Ventures, co-led by LifeCare Partners, with additional investments by all other existing investors, among them Brandenburg Kapital, High-Tech Gründerfonds and Ventura Biomed Investors. Carma Fund joined as a new investor. The proceeds will be used to fund the Phase 1b clinical study of Kupando’s lead candidate, KUP101, in advanced solid tumors and to accelerate its preclinical programs in infectious diseases..

本轮融资再次由 Remiges Ventures 领投，LifeCare Partners 联合领投，所有其他现有投资者也参与了跟投，其中包括 Brandenburg Kapital、High-Tech Gründerfonds 和 Ventura Biomed Investors。Carma Fund 作为新投资者加入。所得资金将用于资助 Kupando 的主要候选药物 KUP101 在晚期实体瘤中的 1b 期临床研究，并加速其在传染病领域的临床前项目。

Kupando’s disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists. Its lead candidate, KUP101, is a differentiated dual TLR 4 and 7 agonist with a robust preclinical profile approaching clinical development.

Kupando的颠覆性方法利用了先天免疫刺激和通过双重Toll样受体（TLR）激动剂诱导训练性先天免疫的力量。其主要候选药物KUP101是一种差异化的双重TLR4和TLR7激动剂，具有强大的临床前特性，正接近临床开发阶段。

KUP101 is ideally suited for the systemic treatment of solid tumors (tissue agnostic), and the prevention and treatment of infectious diseases, including antimicrobial-resistant infections. Its AMR program is being sponsored by the Federal Ministry of Research, Technology and Space..

KUP101非常适合用于实体瘤的系统性治疗（与组织无关），以及预防和治疗传染病，包括抗微生物药物耐药性感染。其AMR项目由联邦研究、技术和航天部赞助。

“We are incredibly grateful for the continued strong support from our existing investors and excited to welcome Carma Fund to the Kupando family,” said Johanna Holldack, MD, Founder and CEO of Kupando. “This additional funding is a testament to the potential of our innovative dual TLR agonist platform and will be instrumental in advancing KUP101 into clinical studies for solid tumors and accelerating our crucial work in infectious diseases.

“我们非常感谢现有投资者一如既往的大力支持，并热烈欢迎Carma基金加入Kupando大家庭，”Kupando创始人兼首席执行官约翰娜·霍尔达克医学博士表示。“这笔额外的资金证明了我们创新的双重TLR激动剂平台的潜力，并将对推动KUP101进入实体瘤临床研究以及加速我们在传染病领域的重要工作起到关键作用。”

Our mission is to leverage the natural resilience of the innate immune system to deliver truly transformative therapies for patients in critical need.”.

我们的使命是利用先天免疫系统的自然韧性，为迫切需要的患者提供真正具有变革性的疗法。

New investor Martin Raditsch, PhD, Managing Partner of Carma Fund, commented, “Kupando’s unique approach to leveraging innate immunity holds immense promise across oncology and infectious diseases. This successful funding round, especially in the current challenging financial climate, underscores the confidence we, as investors, have in Kupando’s science, team, and potential to deliver impactful solutions for unmet medical needs.”.

新投资者、卡玛基金的管理合伙人马丁·拉迪施博士评论道：“库潘多在利用先天免疫方面的独特方法在肿瘤学和传染病领域蕴含着巨大的潜力。这次成功的融资，尤其是在当前充满挑战的金融环境中，彰显了我们作为投资者对库潘多的科学、团队及其满足未竟医疗需求潜力的信心。”

Kazuhiko Nonomura, PhD, Partner of Remiges Ventures and member of Kupando’s Advisory Board, added, “Remiges Ventures is proud to continue leading the investment in Kupando. We believe Kupando’s dual TLR 4 and 7 agonist technology, particularly KUP101, has the potential to redefine treatment paradigms in both cancer and infectious diseases.

野村一彦博士，Remiges Ventures合伙人兼Kupando顾问委员会成员补充道：“Remiges Ventures很荣幸能够继续主导对Kupando的投资。我们相信Kupando的双重TLR 4和7激动剂技术，尤其是KUP101，有潜力重新定义癌症和传染病的治疗模式。”

We are excited to see the company transition to the clinical stage and unlock the full potential of its pipeline.”.

我们很高兴看到公司向临床阶段过渡，并充分释放其产品线的潜力。

Kupando was founded by its CEO Johanna Holldack, MD, driven by the natural resilience observed in animals relying solely on innate immunity. Recognizing the historically undervalued yet critical role of this system, especially with the new understanding of innate and trained immunity, Kupando has made it the core of its therapeutic approach..

库潘多由其首席执行官约翰娜·霍尔达克医学博士创立，灵感来源于仅依赖先天免疫的动物身上观察到的自然恢复力。认识到这一系统历史上被低估但却至关重要的作用，特别是随着对先天免疫和训练免疫的新理解，库潘多已将其作为治疗策略的核心。

https://www.bionity.com/en/news/1188323/biotech-start-up-secures-23-million-total-for-cancer-and-infectious-disease-platform.html

Start-up miRdetect receives seed financing

初创公司miRdetect获得种子轮融资

Consortium invests seven-digit amount in serum marker for testicular cancer detection

财团投资七位数金额用于睾丸癌检测的血清标志物

Read news

读新闻